
BioVersys announces first patient dosed in Phase 2a clinical trial with BVL-GSK098
by Tech Park Basel
31.01.2023
BioVersys AG announces first patient dosed in Phase 2a clinical trial with BVL-GSK099, to investigate a new treatment concept to address multidrug-resistance tuberculosis...